EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma.

: Amplification of the EGFR gene and its truncation mutant EGFRvIII are hallmarks of glioblastoma. Although coexpression of EGFR and EGFRvIII confers a growth advantage, how EGFR and EGFRvIII influence the tumor microenvironment remains incompletely understood. Here, we show that EGFR and EGFRvIII cooperate to induce macrophage infiltration via upregulation of the chemokine CCL2. EGFRvIII was significantly enriched in glioblastoma patient samples with high CCL2, and knockout of CCL2 in tumors coexpressing EGFR and EGFRvIII led to decreased infiltration of macrophages. KRAS was a critical signaling intermediate for EGFR- and EGFRvIII-induced expression of CCL2. Our results illustrate how EGFR and EGFRvIII direct the microenvironment in glioblastoma. SIGNIFICANCE: Full-length EGFR and truncated EGFRvIII work through KRAS to upregulate the chemokine CCL2 and drive macrophage infiltration in glioblastoma.

[1]  G. Reifenberger,et al.  Correction: EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. , 2019, Cancer research.

[2]  B. Barres,et al.  Microglia and macrophages in brain homeostasis and disease , 2017, Nature Reviews Immunology.

[3]  K. Bhat,et al.  The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells , 2017, Front. Oncol..

[4]  A. Shiras,et al.  Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in Glioma , 2017, Front. Oncol..

[5]  K. Frazer,et al.  Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity , 2017, Genes & development.

[6]  Benjamin T. Porebski,et al.  Key determinants of selective binding and activation by the monocyte chemoattractant proteins at the chemokine receptor CCR2 , 2017, Science Signaling.

[7]  Zhihong Chen,et al.  Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. , 2017, Cancer research.

[8]  Yi Zhang,et al.  Tumor-associated macrophages: from basic research to clinical application , 2017, Journal of Hematology & Oncology.

[9]  E. De Carli,et al.  [Immunotherapy in brain tumors]. , 2017, Annales de pathologie.

[10]  Atique U. Ahmed,et al.  CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. , 2016, Cancer research.

[11]  S. Nelander,et al.  Origin of the U87MG glioma cell line: Good news and bad news , 2016, Science Translational Medicine.

[12]  F. C. Bennett,et al.  New tools for studying microglia in the mouse and human CNS , 2016, Proceedings of the National Academy of Sciences.

[13]  M. Nivsarkar,et al.  CD90 a potential cancer stem cell marker and a therapeutic target. , 2016, Cancer biomarkers : section A of Disease markers.

[14]  S. Nelander,et al.  Origin of the U 87 MG glioma cell line : Good news and bad news , 2016 .

[15]  S. Kesari,et al.  An EGFR wild type–EGFRvIII–HB-EGF feed-forward loop regulates the activation of EGFRvIII , 2014, Oncogene.

[16]  H. Haapasalo,et al.  The p38-MK2-HuR pathway potentiates EGFRvIII–IL-1β-driven IL-6 secretion in glioblastoma cells , 2014, Oncogene.

[17]  Jorge Joven,et al.  CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile , 2014, The Journal of Immunology.

[18]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[19]  T. Cloughesy,et al.  Glioblastoma: from molecular pathology to targeted treatment. , 2014, Annual review of pathology.

[20]  G. Reifenberger,et al.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. , 2013, Cancer cell.

[21]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[22]  Jun S. Song,et al.  Sox1 marks an activated neural stem/progenitor cell in the hippocampus , 2012, Development.

[23]  Forest M White,et al.  Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts* , 2012, Molecular & Cellular Proteomics.

[24]  S. Vandenberg,et al.  EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway , 2012, Oncogene.

[25]  Alberto Mantovani,et al.  Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.

[26]  J. Sarkaria,et al.  Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis , 2012, Proceedings of the National Academy of Sciences.

[27]  J. Sarkaria,et al.  Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery , 2011, Current protocols in pharmacology.

[28]  K. Huth,et al.  CD4(+) T-cells are important in regulating macrophage polarization in C57BL/6 wild-type mice. , 2011, Cellular immunology.

[29]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[30]  S. Wong,et al.  Macrophage polarization to a unique phenotype driven by B cells , 2010, European journal of immunology.

[31]  Alexandra Kretz,et al.  Monocyte chemoattractant protein–1 increases microglial infiltration and aggressiveness of gliomas , 2003, Annals of neurology.

[32]  S. Leung,et al.  Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas , 1997, Acta Neuropathologica.